Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFA-279
- Development stage
- Preclinical
- Lead developer
- AfaSci
- Modality
- Small Molecules
01
Overview
AFA-279 is a novel, non-opioid small molecule analgesic developed by AfaSci for the treatment of neuropathic pain. It acts as a potent and selective modulator of T-type calcium channels, specifically targeting the Cav3.2 subunit, which plays a key role in neuronal excitability and pain signaling. Preclinical studies have demonstrated that AFA-279 provides greater analgesic effects than gabapentin in rodent models of neuropathic pain and does not produce common side effects associated with existing pain therapeutics. The drug is currently undergoing IND-enabling studies to support future clinical trials[4][5][1].
02
Targets
CACNA1H (T-type voltage-gated calcium channel 3.2)
Beyond the preview
Go deeper on AFA-279.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFA-279.